PMID- 38422338
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1806-3756 (Electronic)
IS  - 1806-3713 (Linking)
VI  - 50
IP  - 1
DP  - 2024
TI  - Clinical determinants of the modified incremental step test in adults with 
      non-cystic fibrosis bronchiectasis.
PG  - e20230230
LID - S1806-37132024000100602 [pii]
LID - 10.36416/1806-3756/e20230230 [doi]
AB  - OBJECTIVES: This study primarily aimed to investigate the clinical determinants 
      of the Modified Incremental Step Test (MIST) in adults with non-cystic fibrosis 
      bronchiectasis (NCFB). A secondary objective was to compare the cardiopulmonary 
      responses after the MIST and Incremental Shuttle Walk Test (ISWT), two commonly 
      adopted symptom-limited maximum field tests in chronic respiratory diseases. 
      METHODS: Forty-six patients with clinically stable bronchiectasis participated in 
      this cross-sectional study. MIST and ISWT were performed to determine exercise 
      capacity, while disease severity, fatigue, and quality of life were assessed 
      using the Bronchiectasis Severity Index (BSI), the Fatigue Severity Scale (FSS), 
      and St. George's Respiratory Questionnaire (SGRQ), respectively. Quadriceps 
      muscle strength was evaluated using a hand-held dynamometer, walking speed with a 
      wireless inertial sensing device, and the level of physical activity (steps/day) 
      with a pedometer. RESULTS: The BSI score, quadriceps muscle strength, daily step 
      count, and the SGRQ total score explained 61.9% of the variance in the MIST (p < 
      0.001, R2 = 0.67, AR2 = 0.619). The BSI score (r = -0.412, p = 0.004), quadriceps 
      muscle strength (r = 0.574, p = 0.001), daily step count (r = 0.523, p < 0.001), 
      walking speed (r = 0.402, p = 0.006), FSS score (r = -0.551, p < 0.001), and SGRQ 
      total score (r = -0.570, p < 0.001) correlated with the MIST. The patients 
      achieved higher heart rates (HR), HR%, desaturation, dyspnea, and leg fatigue in 
      the MIST compared to the ISWT (p < 0.05). CONCLUSIONS: Disease severity, 
      quadriceps muscle strength, physical activity level, and quality of life were 
      determinants of MIST. The advantages of the MIST, including higher 
      cardiopulmonary response than ISWT and greater portability, which facilitates its 
      use in various settings, make MIST the preferred choice for investigating 
      symptom-limited exercise capacity in patients with NCFB.
FAU - Buran, Melike Mese
AU  - Buran MM
AUID- ORCID: 0000-0002-8089-263X
AD  - . Graduate School of Health Sciences, Dokuz Eylul University, Izmir, Turkey.
FAU - Savci, Sema
AU  - Savci S
AUID- ORCID: 0000-0001-8675-1937
AD  - . Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, 
      Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
FAU - Tanriverdi, Aylin
AU  - Tanriverdi A
AUID- ORCID: 0000-0002-0220-0642
AD  - . Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, 
      Cankiri Karatekin University, Cankiri, Turkey.
FAU - Kahraman, Buse Ozcan
AU  - Kahraman BO
AUID- ORCID: 0000-0002-0192-6740
AD  - . Faculty of Physical Therapy and Rehabilitation, Dokuz Eylul University, Izmir, 
      Turkey.
FAU - Gunduz, Damla
AU  - Gunduz D
AUID- ORCID: 0000-0002-6629-0528
AD  - . Department of Chest Diseases, Faculty of Medicine, Dokuz Eylul University, 
      Izmir, Turkey.
FAU - Sevinc, Can
AU  - Sevinc C
AUID- ORCID: 0000-0003-3691-9150
AD  - . Department of Chest Diseases, Faculty of Medicine, Dokuz Eylul University, 
      Izmir, Turkey.
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20240223
PL  - Brazil
TA  - J Bras Pneumol
JT  - Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de 
      Pneumologia e Tisilogia
JID - 101222274
SB  - IM
MH  - Adult
MH  - Humans
MH  - Exercise Test
MH  - Cross-Sectional Studies
MH  - Quality of Life
MH  - Exercise Tolerance/physiology
MH  - *Bronchiectasis
MH  - *Cystic Fibrosis
MH  - Fibrosis
EDAT- 2024/02/29 18:42
MHDA- 2024/03/04 06:47
CRDT- 2024/02/29 14:44
PHST- 2023/09/22 00:00 [received]
PHST- 2023/11/16 00:00 [accepted]
PHST- 2024/03/04 06:47 [medline]
PHST- 2024/02/29 18:42 [pubmed]
PHST- 2024/02/29 14:44 [entrez]
AID - S1806-37132024000100602 [pii]
AID - 10.36416/1806-3756/e20230230 [doi]
PST - epublish
SO  - J Bras Pneumol. 2024 Feb 23;50(1):e20230230. doi: 10.36416/1806-3756/e20230230. 
      eCollection 2024.